mp3 dönüştür

We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Mo-Rez shows strong early responses in ovarian, endometrial cancers

In an early clinical trial, people with certain advanced or treatment-resistant gynecological cancers showed strong responses to the experimental therapy mocertatug rezetecan (Mo-Rez), according to new data announced by its developer, GSK. Based on these early data,...

FDA grants fast track status to oral therapy for hard-to-treat myeloma

The U.S. Food and Drug Administration (FDA) has granted fast track status to Opna Bio‘s OPN-6602 as a potential treatment for people with multiple myeloma that has come back or failed to respond following at least four prior lines of therapy. The new designation was...

Advocacy group marks AML Awareness Day with interactive webpage launch

AML World Awareness Day, an annual effort to educate people about acute myeloid leukemia (AML), is coming up on April 21, and the advocacy group Know AML — comprised of member organizations from the Americas to Europe, Africa, Asia and Oceania — is marking the day...

Daraxonrasib may offer new hope in previously treated pancreatic cancer

Most people with previously-treated metastatic pancreatic cancer lived for at least one year after receiving the oral therapy candidate daraxonrasib in a clinical trial — a result that daraxonrasib’s developer Revolution Medicines described as an “unprecedented...

Source: Pharmacy Times articles Post Content Read More
Latest Data

Latest Publications

Mapping the Landscape of Quality of Life in Smoldering Multiple Myeloma Clinical Trials: A Systematic Review

Clin Lymphoma Myeloma Leuk. 2026 Mar 16:S2152-2650(26)00070-4. doi: 10.1016/j.clml.2026.03.006....

Concordance and prognostic value of bone-marrow MRD and PET-CT in multiple myeloma: a systematic review and meta-analysis

EClinicalMedicine. 2026 Apr 6;94:103868. doi: 10.1016/j.eclinm.2026.103868. eCollection 2026 Apr....

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review

Am J Hematol. 2026 Apr 2. doi: 10.1002/ajh.70312. Online ahead of print. ABSTRACT Renal impairment...

Prophylactic Immunoglobulin Supplementation for Infection Prevention in Multiple Myeloma: An Updated Systematic Review and Meta-Analysis

Clin Lymphoma Myeloma Leuk. 2026 Mar 6:S2152-2650(26)00066-2. doi: 10.1016/j.clml.2026.03.002....

CLO26-105: Gut Microbiota and Multiple Myeloma: A Systematic Review of Risk, Prognosis, and Therapeutic Implications

J Natl Compr Canc Netw. 2026 Mar 31;24(3.5):CLO26-105. doi: 10.6004/jnccn.2025.7191. NO ABSTRACT...

Email

info@myeloma360.com

bahisliongalabet1xbet